August 12, 2021 -- Medical device company Terumo Blood and Cell Technologies and cancer immunotherapy developer PhotonPharma announced they will work together on a therapeutic vaccine for solid tumors.
The companies have established a memorandum of understanding (MOU) to collaborate on the development of Innocell, a novel tumor-specific immunotherapy for solid-tumor malignancies, including breast cancer. The MOU is the first step of a longer-term collaboration, the companies said.
Illustration of a T-cell (orange) attaching to a cancer cell (blue). Image courtesy of Terumo Blood and Cell Technologies and PhotonPharma.
PhotonPharma is using Terumo's Mirasol pathogen-reduction technology in the manufacturing process to inactivate viruses, bacteria, parasites, and white blood cells that may be present in collected blood products.
PhotonPharma is currently preparing an investigational new drug submission related to a phase I clinical trial of Innocel targeting triple-negative breast cancer. Terumo will supply Mirasol illuminators and single-use sets for the immunotherapy preparation process used in the clinical trial.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
